VERDOT Highlights Collaboration with Moderna

Saint-Beauzire, France, November 10, 2026 - VERDOT, a leading provider of advanced downstream bioprocessing solutions for the biopharmaceutical industry, today highlights its ongoing collaboration with Moderna, one of the world's leading biotechnology companies.

Moderna is collaborating with VERDOT on the design and production of advanced manufacturing units for Intismeran, an investigational individualized mRNA cancer therapy, which will be deployed at Moderna's Marlborough site.

This program highlights VERDOT's distinctive ability to engineer miniaturized fluidic architectures and deliver small-scale systems to GMP standards. A central challenge in small-scale GMP manufacturing is lowering total cost of ownership by shrinking equipment footprint and labor needs through compact design, streamlined operations and automation, all without sacrificing precision, containment, reproducibility or compliance.

"At VERDOT, we believe breakthrough therapies require breakthrough manufacturing solutions. We are proud to collaborate with industry leaders such as Moderna to contribute to the development of this promising immuno-oncology approach, and to bring our expertise in small-scale, mini-fluidic GMP systems, a field that is increasingly critical for mRNA and other advanced therapies. Our new Excellence Center reinforces our ability to support customers over the long term with advanced technologies, expanded capabilities and a relentless focus on innovation."

- Charles Ruban, President and CEO of VERDOT

As part of its long-term commitment to supporting strategic customers, VERDOT recently inaugurated its new Bioproduction Excellence Center in Saint-Beauzire, France. The facility significantly expands the company's engineering, manufacturing, testing and customer support capabilities, providing a strong foundation to support the evolving needs of global biopharmaceutical innovators.

Already recognized as a leading provider of single-use and multi-use purification solutions for all types of biological products, from small scale to large scale, VERDOT continues to invest in technologies that enable the next generation of biomanufacturing, including advanced chromatography and filtration solutions, innovative process architectures, automation and scalable manufacturing platforms.

These investments strengthen VERDOT's ability to support Moderna and other customers advancing increasingly complex biopharmaceutical processes from development through commercial manufacturing.

About VERDOT

VERDOT stands at the forefront of downstream bioprocessing technology. VERDOT provides innovative single-use and stainless-steel purification solutions for the biopharmaceutical industry, including chromatography columns and skids as well as tangential flow filtration (TFF) systems. Ranging from standard to highly customized designs, VERDOT develops solutions for the purification, separation and concentration of biomolecules such as monoclonal antibodies, vaccines, viral vectors (e.g., AAV and lentivirus), and mRNA-based therapeutics.

VERDOT partners with industry leaders in biopharma, research and development, early-stage biotech, and contract development and manufacturing organizations (CDMOs), offering unparalleled expertise across the entire drug development workflow. From initial exploration to the manufacturing of market-ready biologics, VERDOT offers tailored, high-quality purification technologies that enable customers to accelerate time to market for groundbreaking therapies.

For more information about VERDOT, visit www.verdot-biotechnologies.com